This event has passed.

Toronto CLL Support Group

Name: Toronto CLL Support Group
Start: 2020-11-09T19:00:00-05:00
End: 2020-11-09T21:00:00-05:00
Location: Toronto CLL Society Support Group

November 9, 2020 @ 7:00 pm - 9:00 pm

|Recurring Event (See all)

Toronto CLL Support Group

Take a break and read all about it

CLL Society Ed Forum On Demand: CLL Society and Huntsman 5th Annual Patient & Caregiver Educational Forum

In partnership with Huntsman Cancer Institute (HCI), CLL Society invites you to attend our virtual Ed Forum focused on chronic lymphocytic leukemia (CLL). Featured speakers will present the basics of CLL diagnosis, early management, clinical trials, treatment options, COVID-19 considerations for CLL patients, patient perspectives, and strategies to become an effective self-advocate.

Brad Hedrick November 9, 2021

CLL Society Ed Forum On Demand: ASH 2020 Comes to You!

CLL Society Virtual Patient & Caregiver Educational Forum with Dr. Deborah Stephens at Huntsman Cancer Institute on November 14.

Brad Hedrick February 5, 2021

ASH 2022: Dr. Neil Kay on Senescence in CAR-T Cells

This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.

admin March 24, 2023

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).

admin March 24, 2023

ASH 2022: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Tremendous progress over the past decade has been made in managing chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

admin March 24, 2023

Chronic Lymphocytic Leukemia Disclosure 101: Who, When, and What to Say About Your Diagnosis, Treatment, and Prognosis

One afternoon in late March 2013, a group of former colleagues and I were making small talk at a memorial service for Steve, who had just died of a brain tumor.

admin March 24, 2023

Ask Me Anything On Demand – Featuring Dr. Brian Hill and Jeff Folloder

Dr. Brian Hill joins us for CLL Society’s Facebook Live Event “Ask Me Anything”. With no prepared presentation, this event is truly dedicated to answering your questions.

admin March 22, 2023

CLL Society’s COVID-19 Update for the Week of March 20, 2023

CLL Society is going to lessen the number of COVID-19 Updates to monthly at this time, as all trends in numbers right now seem to be on the downward slope. If (and most likely when) another surge in case numbers occur, we will reassess the need to provide more frequent updates again.

Robyn Brumble March 20, 2023

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome

Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.

Brian Koffman March 16, 2023

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity and, in some cases, normal metabolic activity on PET-CT scans, several patients had persistently enlarged lymph nodes.

admin March 16, 2023

ASH 2022: Dr. Jennifer Woyach on Targeting Venetoclax-Resistant Chronic Lymphocytic Leukemia (CLL) with a PROTAC-Based BCL-2/BCL-XL Protein Degrader

A novel PROTAC-based BCL-2/BCL-XL degrader was able to cause cell death in laboratory models of venetoclax-resistant chronic lymphocytic leukemia (CLL).

admin March 16, 2023

Do You Want To Boost Your Business?

drop us a line and keep in touch

Details

Date:: November 9, 2020
Time:: 7:00 pm - 9:00 pm

Venue

Toronto CLL Society Support Group

105 Wellness Way
Toronto, Ontario M3N 0B1 Canada + Google Map

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Toronto CLL Support Group

November 9, 2020 @ 7:00 pm - 9:00 pm

Toronto CLL Support Group

Take a break and read all about it

CLL Society Ed Forum On Demand: CLL Society and Huntsman 5th Annual Patient & Caregiver Educational Forum

CLL Society Ed Forum On Demand: ASH 2020 Comes to You!

ASH 2022: Dr. Neil Kay on Senescence in CAR-T Cells

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

ASH 2022: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Chronic Lymphocytic Leukemia Disclosure 101: Who, When, and What to Say About Your Diagnosis, Treatment, and Prognosis

Ask Me Anything On Demand – Featuring Dr. Brian Hill and Jeff Folloder

CLL Society’s COVID-19 Update for the Week of March 20, 2023

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

ASH 2022: Dr. Jennifer Woyach on Targeting Venetoclax-Resistant Chronic Lymphocytic Leukemia (CLL) with a PROTAC-Based BCL-2/BCL-XL Protein Degrader

Do You Want To Boost Your Business?

drop us a line and keep in touch

Details

Venue

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT